NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

exwannabe,

Let’s clear this up with facts.

The quote I cited comes directly from the official Q1 2025 10-Q, filed on May 15, 2025. It states, verbatim:

“We are also continuing integration of the Flaskworks EDEN system at our manufacturing site, and preparing for additional regulatory filings and inspections relating to this system.”

That’s not paraphrased. That’s not invented. That’s not from a different filing. It’s the actual language from the Q1 10-Q. You claimed “the 10-Q makes no mention of EDEN.” That is objectively false.

Let’s walk through the evolution, using official SEC filings:
• 2022 10-K: NWBO states, “We are working with Flaskworks to prepare comparability testing and validation protocols for submission to the regulators.”
• 2023 10-K: Flaskworks progress is reiterated, with continued preparation language.
• 2024 10-K (filed March 31, 2025): The company states they are continuing comparability testing “in connection with the anticipated inclusion of the Flaskworks system.”
• Q1 2025 10-Q (filed May 15, 2025): EDEN is mentioned by name, with a specific statement about operational integration and preparation for filings and inspections.

This is not a contradiction. It is a regulatory and operational timeline, with clear progression:

• Early reference: Flaskworks (generic)
• Mid-stage: Comparability testing underway
• Current disclosure: Flaskworks EDEN system integration and filings

And yes, EDEN is Flaskworks’ system name — the formal designation of the automated cell therapy manufacturing platform. It’s common in filings for companies to refer to a platform generically first, and then by name as integration becomes material.

As for the accusation that I fabricated a quote: anyone can open the Q1 2025 10-Q and see it for themselves. No AI. No editing. Just the document. This:

“We are also continuing integration of the Flaskworks EDEN system…”

That’s your evidence.

We don’t have to agree on how we interpret NWBO’s strategy. But calling someone a liar for quoting the 10-Q, then turning around and pretending the quote doesn’t exist, is not analysis. It’s spin.

You’re welcome to disagree on meaning. But please stop misrepresenting the filings themselves. That’s not debate. It’s distortion.

Let’s move forward with actual evidence.